NRXP
NASDAQ · Pharmaceuticals
Nrx Pharmaceuticals Inc
$2.33
+0.06 (+2.64%)
Financial Highlights (FY 2026)
Revenue
2.50M
Net Income
-58,400,785
Gross Margin
58.8%
Profit Margin
-2,336.5%
Rev Growth
—
D/E Ratio
1.42
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 58.8% | 65.0% | 65.0% | 65.0% |
| Operating Margin | -1,830.6% | 16.7% | 15.9% | 16.4% |
| Profit Margin | -2,336.5% | 12.5% | 10.0% | 11.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.50M | 21.55M | 19.28M | 24.16M |
| Gross Profit | 1.47M | 14.01M | 12.54M | 15.71M |
| Operating Income | -45,724,518 | 3.59M | 3.06M | 3.97M |
| Net Income | -58,400,785 | 2.70M | 1.92M | 2.84M |
| Gross Margin | 58.8% | 65.0% | 65.0% | 65.0% |
| Operating Margin | -1,830.6% | 16.7% | 15.9% | 16.4% |
| Profit Margin | -2,336.5% | 12.5% | 10.0% | 11.8% |
| Rev Growth | — | +2.0% | +3.7% | +21.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 29.86M | 17.94M | 13.97M | 16.93M |
| Total Equity | 21.02M | 26.88M | 27.54M | 30.17M |
| D/E Ratio | 1.42 | 0.67 | 0.51 | 0.56 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -45,610,602 | 4.73M | 4.55M | 5.86M |
| Free Cash Flow | — | 2.93M | 1.59M | 2.98M |